Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CKDXY - Opthea advances mid-stage study of OPT-302 in diabetic macular edema

CKDXY - Opthea advances mid-stage study of OPT-302 in diabetic macular edema

January, 07 2020 06:36 AM Opthea Ltd ADR

Opthea Limited (OTCPK:CKDXY) completes enrollment in a 117-subject Phase 2a clinical trial evaluating the combination of OPT-302 and Regeneron Pharmaceuticals' Eylea (aflibercept) in diabetic macular edema patients.
More news on: Opthea Limited, Healthcare stocks news,

Stock Information

Company Name:	Opthea Ltd ADR
Stock Symbol:	CKDXY
Market:	OTC

CKDXY CKDXY Quote CKDXY Short CKDXY News CKDXY Articles CKDXY Message Board

Get CKDXY Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.